Education
About Us
Working with TipRanks
Follow Us
Revive Therapeutics Ltd (TSE:RVV)
:RVV
RVV Stock Chart & Stats
C$0.01
C$0.00(0.00%)
At close: 4:00 PM EST
C$0.01
C$0.00(0.00%)
Day’s Range― - ―
52-Week Range<C$0.01 - C$0.04
Previous CloseN/A
Volume2.50K
Average Volume (3M)285.50K
Market Cap
C$6.28M
Enterprise ValueC$6.52M
Total Cash (Recent Filing)C$30.95K
Total Debt (Recent Filing)C$68.18K
Price to Earnings (P/E)―
Beta1.63
Next Earnings
Mar 04, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding418,564,270
10 Day Avg. Volume295,136
30 Day Avg. Volume285,498
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)-2.43
Price to Sales (P/S)0.00
P/FCF Ratio-10.39
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Focused Clinical-stage PipelineA clear R&D focus on psychedelic medicines and drug repurposing gives Revive a concentrated, differentiated pipeline strategy. Clinical-stage assets and in-licensed candidates create durable optionality: successful trials or licensing deals can generate step-change value and allow staged capital deployment tied to program milestones.
Very Low Absolute DebtMinimal nominal debt (about $68K) preserves operational flexibility and reduces interest obligations, lowering short-term default risk. For a pre-revenue biotech, low debt is a durable positive because it limits fixed financial commitments and eases near-term liquidity pressures while management pursues financing or partnerships.
Improving Loss TrajectoryA materially smaller net loss versus recent years signals improved cost control and program prioritization. Sustained reduction in headline losses increases runway per financing round and demonstrates management discipline, a durable operational improvement that reduces dilution risk if maintained through 2–6 months and beyond.
Bears Say
No Revenue / Pre-commercial StageBeing pre-revenue means the company lacks recurring cash inflows and is fully reliant on external capital or milestone payments. This structural reality increases execution risk: until commercial revenue or sustainable licensing streams materialize, financing needs and trial outcomes will drive long-term viability and strategic choices.
Negative Shareholders' Equity & Shrunken AssetsNegative equity and a dramatic drop in reported assets materially weaken the balance sheet, limiting collateral for lenders and increasing refinancing risk. This structural deterioration reduces financial flexibility and makes it harder to secure non-dilutive funding or favorable terms, elevating long-term solvency concerns.
Persistent Cash Burn; Not Self-fundingOngoing negative operating and free cash flow means the business requires external capital to continue operations. Even with reduced burn versus earlier years, persistent negative FCF is a durable risk driver: continued dependence on financings increases dilution risk and can constrain R&D pacing or strategic choices over the medium term.
Revive Therapeutics News
RVV FAQ
What was Revive Therapeutics Ltd’s price range in the past 12 months?
Revive Therapeutics Ltd lowest stock price was <C$0.01 and its highest was C$0.04 in the past 12 months.
What is Revive Therapeutics Ltd’s market cap?
Revive Therapeutics Ltd’s market cap is C$6.28M.
When is Revive Therapeutics Ltd’s upcoming earnings report date?
Revive Therapeutics Ltd’s upcoming earnings report date is Mar 04, 2026 which is in 6 days.
How were Revive Therapeutics Ltd’s earnings last quarter?
Currently, no data Available
Is Revive Therapeutics Ltd overvalued?
According to Wall Street analysts Revive Therapeutics Ltd’s price is currently Overvalued.
Does Revive Therapeutics Ltd pay dividends?
Revive Therapeutics Ltd does not currently pay dividends.
What is Revive Therapeutics Ltd’s EPS estimate?
Revive Therapeutics Ltd’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Revive Therapeutics Ltd have?
Revive Therapeutics Ltd has 418,564,270 shares outstanding.
What happened to Revive Therapeutics Ltd’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Revive Therapeutics Ltd?
Currently, no hedge funds are holding shares in TSE:RVV
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Revive Therapeutics Ltd
Revive Therapeutics Ltd., a life sciences company, focuses on the research and development of therapeutics for rare disorders and infectious diseases. The company offers cannabinoid pharmaceutical portfolio that focuses on rare inflammatory diseases. It is developing Bucillamine, which is in Phase 3 clinical study for the treatment of infectious diseases, including influenza and COVID-19; Psilocybin that is in Phase 1 clinical study for treating methamphetamine use disorder; Psilocin for the treatment of depression, anxiety, bi-polar disorder, bulimia and anorexia nervosa, and other diseases; and cannabidiol for treating autoimmune hepatitis and ischemia and reperfusion injury from organ transplantation. Revive Therapeutics Ltd. has research collaboration agreements with PharmaTher Inc. for the development of psilocybin in the treatment of cancer and the discovery of other uses of undisclosed psychedelic compounds; North Carolina State University for the development of a biosynthetic version of psilocybin based on a natural biosynthesis enzymatic platform; the University of California, San Francisco to explore the use of Bucillamine as a treatment for severe COVID-19; University of Health Sciences Antigua for the clinical research of psychedelics; and PharmaTher for the development of psilocybin microneedle patch. The company was incorporated in 2012 and is headquartered in Toronto, Canada.
Technical Analysis
Options Prices
Currently, No data available
---